financial results for the fiscal year 2017 (fy201...mar 31, 2018 · share of profits/losses of...

Supplementary Documents [IFRS]

Financial results for the fiscal year 2017 (FY2017)

Astellas Pharma Inc.

- FY2017 Financial Results

For the year ended March 31, 2018

Three months ended March 31, 2018

- Pipeline list

- Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are

forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in

light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results

to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general

economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new

product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively

research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by

third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to

constitute an advertisement or medical advice.

38

[For the year ended March 31,2018]1. Consolidated Results (Full Basis)

Unit: B¥ Unit: B¥ Forecasts

Change from

FY17

FY16 FY17 Change Change FY17 FY18 Change

Full Year Full Year (%) Revised Forecasts Full Year (%)

Sales 1,311.7 1,300.3 -11.3 -0.9% 1,297.0 1,278.0 -1.7%

Cost of sales 320.5 294.2 -26.3 -8.2%

Ratio to Sales 24.4% 22.6%

Gross profit 991.2 1,006.1 14.9 1.5%

SG&A expenses 470.8 478.3 7.6 1.6%


Advertising and Sales Promotion 144.1 152.1 8.0 5.6%

Personnel expenses 177.0 178.5 1.5 0.8%

Other 149.7 147.7 -2.0 -1.3%

R&D expenses 208.1 220.8 12.7 6.1% 218.0 214.0 -3.1%

Ratio to Sales 15.9% 17.0% 16.8% 16.7%

Amortisation of intangible assets 35.8 35.8 0.0 0.0%

Share of profits/losses of associates and joint ventures -1.9 -2.4 -0.6 -

Other income 9.6 11.9 2.3 23.7%

Fair value remeasurements on contingent consideration - 1.2 1.2 -

Gain from remeasurement relating to business combinations - 5.9 5.9 -

Other expense 23.3 67.3 44.0 188.7%

Impairment losses 18.1 42.4 24.3 134.7%

Restructuring costs 3.1 9.2 6.0 193.6%

Net foreign exchange losses - 10.5 10.5 -

Fair value remeasurements on contingent consideration - 1.2 1.2 -

Operating profit 260.8 213.3 -47.6 -18.2% 222.0 265.0 24.3%

Ratio to Sales 19.9% 16.4% 17.1% 20.7%

Finance income 22.9 6.6 -16.3 -71.0%

Gain on sales of available-for-sale financial assets 21.3 4.7 -16.5 -77.7%

Finance expense 2.0 1.8 -0.2 -9.8%

Impairment losses for available-for-sale financial assets 0.6 0.5 -0.2 -26.2%

Profit before tax 281.8 218.1 -63.7 -22.6% 228.0 266.0 22.0%

Ratio to Sales 21.5% 16.8% 17.6% 20.8%

Income tax expense 63.1 53.4 -9.6 -15.3%

Profit for the year 218.7 164.7 -54.0 -24.7% 180.0 213.0 29.3%

Ratio to Sales 16.7% 12.7% 13.9% 16.7%

Comprehensive income 174.6 198.5 23.9 13.7%

39


Change from

FY17

2. Consolidated Results (Core Basis) FY16 FY17 Change Change FY17 FY18 Change


Sales 1,311.7 1,300.3 -11.3 -0.9% 1,297.0 1,278.0 -1.7%

Cost of sales 320.5 294.2 -26.3 -8.2%


Gross profit 991.2 1,006.1 14.9 1.5%

SG&A expenses 470.8 478.3 7.6 1.6%


Advertising and Sales Promotion 144.1 152.1 8.0 5.6%

Personnel expenses 177.0 178.5 1.5 0.8%

Other 149.7 147.7 -2.0 -1.3%

R&D expenses 208.1 220.8 12.7 6.1% 218.0 214.0 -3.1%

Ratio to Sales 15.9% 17.0% 16.8% 16.7%

Amortisation of intangible assets 35.8 35.8 0.0 0.0%

Share of profits/losses of associates and joint ventures -1.9 -2.4 -0.6 -

Operating profit 274.6 268.7 -5.9 -2.1% 258.0 262.0 -2.5%

Ratio to Sales 20.9% 20.7% 19.9% 20.5%

Finance income 1.7 1.9 0.2 14.5%

Finance expense 1.3 1.2 -0.1 -8.1%

Profit before Tax 274.9 269.4 -5.5 -2.0%


Income tax expense 61.6 65.1 3.5 5.7%

Profit for the year 213.3 204.3 -9.0 -4.2% 201.0 210.0 2.8%

Ratio to Sales 16.3% 15.7% 15.5% 16.4%

3. Exchange Rate Unit: yen Unit: yen Forecasts

FY16 FY17 FY16 FY17 FY17 FY18

Ave. Ave. End End Revised Forecasts Full Year

USD/Yen 108 111 112 106 111 105

EUR/Yen 119 130 120 131 128 130

* Exchange rate fluctuations had positive impact by 43.3 billion yen on sales and positive impact by 13.1 billion yen on Core operating profit in FY2017

40

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

Full basis Adjustment Core basis Full basis Adjustment Core basis

Sales 1,311.7 - 1,311.7 1,300.3 - 1,300.3

Cost of sales 320.5 - 320.5 294.2 - 294.2

Gross profit 991.2 - 991.2 1,006.1 - 1,006.1

SG&A expenses 470.8 - 470.8 478.3 - 478.3

R&D expenses 208.1 - 208.1 220.8 - 220.8

Amortisation of intangible assets 35.8 - 35.8 35.8 - 35.8

Share of losses of associates and joint ventures -1.9 - -1.9 -2.4 - -2.4

Other income *1 9.6 -9.6 - 11.9 -11.9 -

Other expense *1 23.3 -23.3 - 67.3 -67.3 -

Operating profit 260.8 13.7 274.6 213.3 55.4 268.7

Finance income *2 22.9 -21.3 1.7 6.6 -4.7 1.9

Finance expense *2 2.0 -0.7 1.3 1.8 -0.6 1.2

Profit before tax 281.8 -6.9 274.9 218.1 51.3 269.4

Income tax expense 63.1 -1.5 61.6 53.4 11.6 65.1

Profit for the year 218.7 -5.4 213.3 164.7 39.6 204.3

*1. “Other income” and “Other expense” are excluded from Core results. “Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses, loss on the restructuring, litigation costs and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results as non-core items.

FY17FY16

41

5. Sales by Region Unit: B¥ Unit: B¥ Forecasts

Change from

FY17



Sales 1,311.7 1,300.3 -11.3 -0.9% 1,297.0 1,278.0 -1.7%

Japan 480.8 421.2 -59.6 -12.4% 423.0 396.8 -5.8%

Ratio to Sales 36.7% 32.4% 32.6% 31.0%

Americas 412.4 433.3 20.9 5.1% 432.9 424.4 -2.1%

Ratio to Sales 31.4% 33.3% 33.4% 33.2%

EMEA 330.8 343.8 13.0 3.9% 339.7 343.9 0.0%

Ratio to Sales 25.2% 26.4% 26.2% 26.9%

Asia and Oceania 87.7 102.0 14.3 16.3% 101.4 112.9 10.7%

Ratio to Sales 6.7% 7.8% 7.8% 8.8%

- Calculated according to locations of sellers.

- EMEA: Europe, Middle East and Africa

6. Per Share Information Forecasts

FY16 FY17 FY17 FY18

Full Year Full Year Revised Forecasts Full Year

The number of shares issued (thousand) 2,153,823 2,068,823

Treasury Shares (thousand) 88,817 92,670

The number of shares issued after deducting Treasury Shares (thousand) 2,065,005 1,976,152

Earnings per share (yen) 103.69 81.11 88.15 107.79

Earnings per share (yen) core base 101.15 100.64 98.43 106.27

Dividend per share (yen) 34 36 36 38

Return on Equity (%) 17.3% 13.0%

Dividend on Earnings (%) 5.6% 5.7%

7. Addition to Property,Plant and Equipment, Depreciation/Amortisation


Change from

FY17



Addition to Property, Plant and Equipment

Consolidated 23.9 24.1 0.2 0.9% 25.0 27.0 12.0%

Depreciation (PP&E)

Consolidated 21.9 22.0 0.2 0.8% 23.0 22.0 -0.2%

Amortisation (Intangible Assets) *

Consolidated 41.9 42.8 0.9 2.2% 42.0 40.0 -6.6%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

42

8. Sales of major products

1) Sales of global products Unit: B¥ Unit: B¥ Forecasts

Change from

FY17



XTANDI 252.1 294.3 42.2 16.8% 291.3 310.3 5.5%

US 131.7 144.4 12.7 9.7% 140.4 142.3 -1.4%

ex-US 120.4 149.9 29.5 24.5% 151.0 168.1 12.1%

Japan 23.4 26.1 2.7 11.4% 25.9 28.2 8.2%

Americas (ex-US) 7.7 11.3 3.5 45.7% 11.0 12.4 10.5%

EMEA 85.3 106.7 21.4 25.1% 108.4 119.7 12.2%

Asia and Oceania 4.0 5.8 1.9 47.3% 5.6 7.7 31.0%

Eligard 15.9 16.5 0.6 3.8% 18.3 17.0 2.9%

EMEA 15.7 16.1 0.5 3.0% 17.8 16.4 1.7%

Asia and Oceania 0.2 0.4 0.1 55.9% 0.5 0.6 56.1%

Vesicare 116.1 102.3 -13.8 -11.9% 106.2 96.9 -5.2%

Japan 25.6 23.9 -1.7 -6.8% 24.0 22.7 -4.8%

Americas 53.1 41.3 -11.8 -22.3% 45.5 39.5 -4.1%

EMEA 32.0 31.7 -0.4 -1.2% 31.0 29.7 -6.0%

Asia and Oceania 5.0 5.0 0.0 0.4% 5.2 4.5 -11.2%

Betanis/Myrbetriq/BETMIGA 98.8 125.7 26.9 27.2% 126.1 146.2 16.3%

Japan 25.9 29.5 3.6 13.7% 29.6 32.0 8.8%

Americas 55.3 72.8 17.5 31.7% 72.8 84.7 16.3%

EMEA 14.1 18.3 4.1 29.4% 18.3 22.0 20.4%

Asia and Oceania 3.5 5.2 1.7 47.7% 5.4 7.5 43.0%

Harnal/Omnic 47.7 49.6 2.0 4.1% 50.8 46.9 -5.4%

Sales by Astellas 45.4 47.5 2.1 4.6% 48.9 45.8 -3.5%

Japan 9.2 7.4 -1.7 -19.0% 7.4 5.1 -31.7%

EMEA 14.1 15.7 1.7 11.9% 16.1 15.8 0.1%

Asia and Oceania 21.1 23.2 2.1 10.1% 24.2 23.8 2.4%

Bulk and Royalties 2.3 2.2 -0.1 -5.8% 1.9 1.1 -47.0%

Prograf 186.2 198.5 12.3 6.6% 194.8 190.7 -3.9%

Sales by Astellas 183.5 195.2 11.6 6.3% 191.8 188.9 -3.2%

Japan (Including Graceptor) 48.8 48.3 -0.6 -1.1% 48.8 46.3 -4.1%

Americas 27.3 25.7 -1.6 -5.9% 25.5 20.1 -21.8%

EMEA 70.1 78.7 8.6 12.2% 77.2 76.0 -3.4%

Advagraf 30.0 35.3 5.4 17.9%

Asia and Oceania 37.3 42.5 5.2 14.0% 40.3 46.5 9.3%

Exports to third parties 2.6 3.3 0.7 25.4% 3.0 1.8 -46.2%

Funguard/MYCAMINE 40.3 41.0 0.7 1.9% 40.3 34.8 -15.2%

Japan 11.2 10.6 -0.6 -5.7% 11.0 7.8 -26.3%

Americas 12.2 12.3 0.1 0.8% 11.3 9.9 -19.5%

EMEA 10.8 11.6 0.8 7.6% 11.0 9.1 -21.5%

Asia and Oceania 6.0 6.4 0.5 7.7% 7.0 7.9 22.9%

- Sales of products in Japan are shown in a gross sales basis.


43

2) Sales of products in Japan Unit: B¥ Unit: B¥ Forecasts

Change from

FY17


<Global products> Full Year Full Year (%) Revised Forecasts Full Year (%)

XTANDI 23.4 26.1 2.7 11.4% 25.9 28.2 8.2%

Vesicare 25.6 23.9 -1.7 -6.8% 24.0 22.7 -4.8%

Betanis 25.9 29.5 3.6 13.7% 29.6 32.0 8.8%

Harnal 9.2 7.4 -1.7 -19.0% 7.4 5.1 -31.7%

Prograf （Including Graceptor ） 48.8 48.3 -0.6 -1.1% 48.8 46.3 -4.1%

Funguard 11.2 10.6 -0.6 -5.7% 11.0 7.8 -26.3%

<Local products in Japan>

Micardis [Family] 93.2 46.3 -46.9 -50.3% 49.4 17.7 -61.7%

Micombi 9.4 4.9 -4.5 -47.8%

Micamlo 26.2 13.8 -12.4 -47.5%

Celecox 47.6 48.3 0.8 1.6% 48.2 49.4 2.1%

Symbicort 39.3 39.5 0.2 0.6% 39.8

Bonoteo 13.8 13.3 -0.5 -3.6% 13.2 10.4 -21.7%

Geninax 10.1 9.2 -1.0 -9.4% 10.0 8.7 -5.2%

Vaccines 34.5 29.4 -5.1 -14.9% 30.5 36.8 25.4%

Argamate 5.8 5.8 -0.1 -1.0% 5.8 5.3 -7.5%

Gonax 4.5 4.7 0.2 3.9% 4.8 5.1 9.2%

Cimzia 7.7 9.0 1.2 16.2% 8.8 9.8 8.8%

Suglat 9.5 11.6 2.1 22.5% 11.7 13.3 13.9%

Repatha 1.6

Linzess 1.4 9.2 562.7%

Lipitor 23.2 19.6 -3.6 -15.3% 19.7 15.3 -21.9%

Myslee 14.7 13.3 -1.4 -9.5% 13.2 10.9 -18.1%

Seroquel 7.5 6.2 -1.3 -17.7% 6.1 4.5 -27.6%

Total Rx Sales In Japanese market 452.7 383.4 -69.4 -15.3% 387.0 365.3 -4.7%



Change from

FY17

3) Sales of products in Americas and EMEA FY16 FY17 Change Change FY17 FY18 Change


Tarceva 35.2 29.7 -5.6 -15.8%

(US) 25.8 21.5 -4.3 -16.8%

(ex-US) 9.4 8.2 -1.2 -13.0%

Scan (Americas) 71.5 73.6 2.1 2.9% 72.6 69.4 -5.7%

AmBisome (Americas) 10.5 11.4 0.8 7.9% 11.1 11.5 1.2%

CRESEMBA (Americas) 5.8 9.6 3.8 66.4% 8.8 10.5 8.8%

44

4) Sales in Americas and EMEA (Local currency) Unit: M$ Unit:M$ Forecasts

Change from

FY17


Americas Full Year Full Year (%) Revised Forecasts Full Year (%)

Sales 3,805 3,909 104 2.7% 3,917 4,042 3.4%

XTANDI 1,286 1,404 118 9.2% 1,370 1,474 5.0%

US 1,215 1,303 88 7.2% 1,270 1,355 4.0%

Americas (ex-US) 71 102 30 42.4% 100 119 16.7%

Tarceva 325 268 -58 -17.7%

US 238 194 -44 -18.7%

ex-US 87 74 -13 -15.0%

VESIcare 490 372 -118 -24.0% 411 377 1.2%

Myrbetriq 510 657 147 28.7% 658 806 22.8%

Prograf 252 232 -20 -8.0% 231 191 -17.4%

Scan 660 664 4 0.6% 657 661 -0.4%

MYCAMINE 113 111 -2 -1.4% 102 94 -15.1%

AmBisome 97 102 5 5.5% 100 109 6.8%

CRESEMBA 53 87 33 62.7% 80 100 14.9%

Unit: M€ Unit:M€ Forecasts

Change from

FY17


EMEA Full Year Full Year (%) Revised Forecasts Full Year (%)

Sales 2,785 2,651 -134 -4.8% 2,651 2,645 -0.2%

XTANDI 718 823 105 14.6% 846 921 11.9%

Eligard 132 125 -7 -5.6% 139 126 1.4%

Vesicare 270 244 -26 -9.5% 242 229 -6.3%

BETMIGA 119 141 22 18.5% 143 169 20.1%

Omnic 138 138 0 0.2% 140 130 -5.8%

Sales by Astellas 118 121 3 2.5% 125 121 -0.2%

Bulk and Royalties 19 17 -3 -13.8% 15 9 -47.2%

Prograf 612 632 20 3.2% 626 598 -5.4%

Sales by Astellas 590 607 17 2.8% 602 584 -3.6%

Advagraf 252 272 20 8.0%

Exports to third parties 22 25 3 14.8% 24 14 -46.3%

MYCAMINE 91 90 -1 -1.5% 86 70 -21.7%


45

9.Consolidated statements of financial position

Unit: B¥

Amount Amount Change

Assets 1,814.1 1,858.2 44.1

Non-current assets 937.4 1,012.6 75.2

Property, plant and equipment 191.1 181.3 -9.8

Goodwill 168.5 213.0 44.5

Other intangible assets 387.4 416.9 29.5

Trade and other receivables 22.3 25.3 3.0

Investments in associates and joint ventures 3.0 3.1 0.2

Deferred tax assets 90.3 97.2 6.9

Other financial assets 61.6 67.4 5.8

Other non-current assets 13.2 8.4 -4.8

Current assets 876.7 845.6 -31.0

Inventories 182.5 147.6 -34.9

Trade and other receivables 309.8 319.5 9.7

Income tax receivable 11.0 8.4 -2.6

Other financial assets 13.6 13.5 -0.0

Other current assets 18.8 14.4 -4.4

Cash and cash equivalents 340.9 331.7 -9.2

Assets held for sale - 10.4 10.4

Due to the adjustments of the provisional fair value for the acquisition of Ganymed Pharmaceuticals AG , consolidated

statement of financial position as of 31 March, 2017 was retrospectively revised.

For the details, refer to Financial Results P.29

31-Mar-1831-Mar-17

46

Unit: B¥

Amount Amount Change

Equity and Liabilities 1,814.1 1,858.2 44.1

Equity 1,271.8 1,268.3 -3.5

Equity attributable to owners of the parent 1,271.8 1,268.3 -3.5

Share capital 103.0 103.0 -

Capital surplus 177.1 177.2 0.1

Treasury shares -138.2 -136.0 2.3

Retained earnings 1,013.9 976.1 -37.8

Other components of equity 116.0 147.9 31.9

Liabilities 542.3 589.9 47.7

Non-current liabilities 142.4 168.3 25.9

Trade and other payables 0.4 3.5 3.1

Deferred tax liabilities 18.5 26.4 7.9

Retirement benefit liabilities 36.6 36.7 0.1

Provisions 4.9 4.9 -0.0

Other financial liabilities 28.4 49.4 21.0

Other non-current liabilities 53.5 47.4 -6.2

Current liabilities 399.9 421.6 21.8

Trade and other payables 182.8 140.9 -41.9

Income tax payable 10.9 25.2 14.3

Provisions 96.6 126.2 29.6

Other financial liabilities 3.0 7.6 4.6

Other current liabilities 106.5 121.7 15.2

31-Mar-17 31-Mar-18

47

10. Employees Number of employees

FY16 FY17

End End

Total 17,202 16,617

Japan 7,029 6,825

Americas 3,016 2,840

EMEA 4,672 4,490

Asia and Oceania 2,485 2,462

Total Medical Representatives 5,750 5,330


11. Shareholders

FY16 FY17

End End

Banks 30.7% 32.3%

Securities 3.5% 3.5%

Other companies 3.4% 3.2%

Foreign companies 49.3% 47.3%

Individuals and others 9.1% 9.3%

Treasury Stock* 4.1% 4.4%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust.

48

[For the year ended March 31,2018]1. Consolidated Results (Full Basis) Unit: B¥

FY17

APR.-JUN. Change JUL.-SEP. Change OCT.-DEC. Change JAN.-MAR. Change

(Quarterly) (%) (Quarterly) (%) (Quarterly) (%) (Quarterly) (%)

Sales 322.6 -4.5% 317.2 1.0% 359.7 1.6% 300.9 -1.7%

Cost of sales 79.3 10.9% 69.5 -7.0% 90.1 -13.8% 55.3 -20.7%

Ratio to Sales 24.6% 21.9% 25.1% 18.4%

Gross profit 243.3 -8.6% 247.6 3.5% 269.6 8.1% 245.5 3.9%

SG&A expenses 112.3 0.4% 116.0 6.4% 121.7 5.1% 128.3 -4.3%

Ratio to Sales 34.8% 36.6% 33.8% 42.6%

Advertising and Sales Promotion 34.6 -3.5% 37.7 13.1% 39.4 9.7% 40.4 3.8%

Personnel expenses 43.6 0.3% 44.4 5.8% 44.2 -0.1% 46.2 -2.2%

Other 34.1 4.8% 33.8 0.7% 38.1 6.9% 41.7 -13.0%

R&D expenses 56.5 10.7% 51.0 4.8% 54.1 11.4% 59.2 -1.1%

Ratio to Sales 17.5% 16.1% 15.1% 19.7%

Amortisation of intangible assets 9.0 -0.1% 9.0 2.8% 9.1 0.3% 8.8 -2.8%

Share of profits/losses of associates and joint ventures -0.4 - -0.5 - -0.6 - -1.0 -

Other income 9.7 - 0.3 106.6% 0.6 -91.0% 10.0 231.9%

Fair value remeasurements on contingent consideration 9.2 - 0.3 - 0.2 - 0.1 -

Gain from remeasurement relating to business combinations - - - - - - 5.9 -

Other expense 31.3 - 19.0 124.4% 1.0 -86.9% 24.7 299.6%

Impairment losses 26.0 - 10.8 41.5% 0.5 -87.5% 5.1 -17.3%

Restructuring costs -0.1 - 3.3 334.5% 0.4 -82.4% 5.6 -

Net foreign exchange losses 5.1 - 3.5 - - - 2.1 -

Fair value remeasurements on contingent consideration - - - - - - 9.8 -

Operating profit 43.5 -53.1% 52.5 -18.1% 83.7 12.7% 33.5 13.4%

Ratio to Sales 13.5% 16.6% 23.3% 11.1%

Finance income 5.2 328.9% 0.4 -65.1% 0.4 -96.4% 0.6 -93.4%

Gain on sales of available-for-sale financial assets 4.7 628.1% 0.0 -99.8% - - - -

Finance expense 0.3 -68.8% 0.2 -73.7% 0.7 -384.4% 0.6 6.2%

Impairment losses for available-for-sale financial assets 0.0 -99.5% 0.0 -85.0% 0.5 - - -

Profit before tax 48.5 -48.0% 52.8 -18.3% 83.4 -3.2% 33.5 -11.5%

Ratio to Sales 15.0% 16.6% 23.2% 11.1%

Income tax expense 6.0 -77.4% 13.1 -18.8% 22.9 2.2% 11.4 -663.8%

Profit for the year 42.5 -36.2% 39.6 -18.2% 60.5 -5.1% 22.1 -44.7%

Ratio to Sales 13.2% 12.5% 16.8% 7.3%

Comprehensive income 83.5 - 80.6 119.9% 72.9 -56.6% -38.6 -

49

2. Consolidated Results (Core Basis) Unit: B¥

FY17



Sales 322.6 -4.5% 317.2 1.0% 359.7 1.6% 300.9 -1.7%

Cost of sales 79.3 10.9% 69.5 -7.0% 90.1 -13.8% 55.3 -20.7%

Ratio to Sales 24.6% 21.9% 25.1% 18.4%

Gross profit 243.3 -8.6% 247.6 3.5% 269.6 8.1% 245.5 3.9%

SG&A expenses 112.3 0.4% 116.0 6.4% 121.7 5.1% 128.3 -4.3%

Ratio to Sales 34.8% 36.6% 33.8% 42.6%

Advertising and Sales Promotion 34.6 -3.5% 37.7 13.1% 39.4 9.7% 40.4 3.8%

Personnel expenses 43.6 0.3% 44.4 5.8% 44.2 -0.1% 46.2 -2.2%

Other 34.1 4.8% 33.8 0.7% 38.1 6.9% 41.7 -13.0%

R&D expenses 56.5 10.7% 51.0 4.8% 54.1 11.4% 59.2 -1.1%

Ratio to Sales 17.5% 16.1% 15.1% 19.7%

Amortisation of intangible assets 9.0 -0.1% 9.0 2.8% 9.1 0.3% 8.8 -2.8%

Share of profits/losses of associates and joint ventures -0.4 - -0.5 - -0.6 - -1.0 -

Operating profit 65.1 -30.7% 71.2 -1.8% 84.1 11.6% 48.2 47.4%

Ratio to Sales 20.2% 22.5% 23.4% 16.0%

Finance income 0.5 -15.2% 0.4 69.4% 0.4 -18.0% 0.6 75.4%

Finance expense 0.2 -59.0% 0.2 -71.9% 0.2 -190.6% 0.5 81.5%

Profit before Tax 65.4 -30.4% 71.4 -0.9% 84.3 10.6% 48.3 47.4%

Ratio to Sales 20.3% 22.5% 23.4% 16.1%

Income tax expense 13.4 -49.8% 16.7 -10.3% 23.0 17.8% 11.9 -451.8%

Profit for the year 51.9 -22.7% 54.7 2.4% 61.2 8.2% 36.4 0.8%

Ratio to Sales 16.1% 17.3% 17.0% 12.1%

50

3. Sales by Region Unit: B¥

FY17



Sales 322.6 -4.5% 317.2 1.0% 359.7 1.6% 300.9 -1.7%

Japan 114.2 -8.1% 98.8 -12.5% 124.3 -13.0% 83.9 -16.7%

Ratio to Sales 35.4% 31.1% 34.6% 27.9%

Americas 101.6 -5.6% 106.8 7.8% 118.5 16.8% 106.5 2.1%

Ratio to Sales 31.5% 33.7% 32.9% 35.4%

EMEA 83.4 -2.3% 85.7 6.1% 91.0 4.7% 83.7 7.5%

Ratio to Sales 25.9% 27.0% 25.3% 27.8%

Asia and Oceania 23.4 13.2% 25.9 22.9% 25.9 14.3% 26.7 15.2%

Ratio to Sales 7.3% 8.2% 7.2% 8.9%

- Calculated according to locations of sellers.


4. Addition to Property,Plant and Equipment

Depreciation/Amortisation Unit: B¥

FY17



Addition to Property, Plant and Equipment

Consolidated 5.8 48.4% 4.6 -8.1% 6.7 44.0% 7.0 -32.1%

Depreciation (PP&E)

Consolidated 5.4 -3.0% 5.6 3.5% 5.4 -0.7% 5.8 3.3%

Amortisation (Intangible Assets) *

Consolidated 10.6 1.8% 10.7 5.0% 10.8 1.8% 10.7 0.2%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

51

5. Sales of major products Unit: B¥

1) Sales of global products FY17



XTANDI 67.9 5.8% 72.4 17.2% 79.6 25.8% 74.4 18.4%

US 33.4 -6.5% 34.9 7.1% 39.9 24.2% 36.2 15.8%

ex-US 34.5 21.1% 37.5 28.5% 39.8 27.5% 38.2 20.9%

Japan 6.5 7.0% 6.4 11.6% 7.2 15.3% 6.0 11.6%

Americas (ex-US) 2.5 40.0% 2.8 59.4% 3.3 99.7% 2.6 4.5%

EMEA 24.4 22.1% 26.9 29.3% 27.8 24.2% 27.7 24.9%

Asia and Oceania 1.2 62.9% 1.4 60.4% 1.5 61.6% 1.8 23.2%

Eligard 4.4 -0.6% 4.0 16.2% 4.3 3.0% 3.8 -1.3%

EMEA 4.3 -1.1% 3.9 15.8% 4.2 2.1% 3.7 -2.5%

Asia and Oceania 0.1 39.7% 0.1 35.1% 0.1 71.3% 0.1 86.7%

Vesicare 24.6 -19.2% 25.1 -14.4% 28.8 -2.3% 23.8 -11.2%

Japan 6.4 -8.0% 5.7 -4.7% 6.7 -4.1% 5.0 -10.7%

Americas 9.3 -31.4% 10.4 -26.1% 12.3 -4.4% 9.2 -26.5%

EMEA 7.5 -13.8% 7.5 -4.3% 8.2 1.0% 8.4 14.4%

Asia and Oceania 1.3 9.7% 1.2 5.7% 1.3 -4.5% 1.2 -7.7%

Betanis/Myrbetriq/BETMIGA 27.2 15.6% 30.4 37.1% 35.5 36.9% 32.6 20.0%

Japan 7.2 12.3% 6.9 16.8% 8.4 15.8% 7.0 9.8%

Americas 15.0 15.9% 17.8 46.7% 20.8 49.4% 19.2 17.8%

EMEA 3.9 12.1% 4.4 29.6% 5.0 32.4% 5.0 43.3%

Asia and Oceania 1.1 60.3% 1.3 74.3% 1.4 33.0% 1.5 36.1%

Harnal/Omnic 12.1 -0.3% 13.3 17.0% 12.7 4.4% 11.5 -3.9%

Sales by Astellas 11.8 2.3% 12.3 12.5% 12.3 4.0% 11.1 0.0%

Japan 2.1 -18.6% 1.9 -15.3% 2.0 -17.3% 1.4 -26.3%

EMEA 3.8 5.1% 4.0 27.5% 4.0 8.0% 3.9 9.3%

Asia and Oceania 5.7 9.6% 6.1 15.0% 5.9 10.1% 5.6 5.8%

Bulk and Royalties 0.3 -49.2% 0.9 152.1% 0.4 19.4% 0.5 -49.1%

Prograf 49.4 0.0% 49.8 11.3% 50.9 5.9% 48.3 10.0%

Sales by Astellas 48.1 -1.2% 49.0 11.5% 50.4 5.8% 47.7 10.2%

Japan (Including Graceptor) 12.7 -1.5% 12.3 3.5% 13.3 0.4% 9.9 -7.8%

Americas 6.2 -18.8% 6.2 -3.5% 6.4 -2.2% 6.8 2.9%

EMEA 19.6 3.1% 19.8 19.5% 20.1 12.7% 19.1 15.0%

Advagraf 8.6 9.3% 9.1 27.4% 9.3 22.3% 8.3 13.3%

Asia and Oceania 9.5 5.0% 10.6 18.1% 10.6 6.0% 11.9 27.4%

Exports to third parties 1.4 81.1% 0.9 1.2% 0.5 13.3% 0.6 -1.8%

Funguard/MYCAMINE 10.3 2.1% 10.6 5.4% 10.7 0.7% 9.4 -0.9%

Japan 2.7 -0.5% 2.8 -3.3% 3.0 -7.9% 2.0 -11.8%

Americas 3.0 -3.0% 2.9 0.9% 3.4 8.8% 3.1 -3.2%

EMEA 2.9 5.5% 3.2 13.6% 2.8 0.2% 2.7 11.6%

Asia and Oceania 1.6 11.5% 1.7 15.6% 1.5 4.3% 1.6 0.0%



52

2) Sales of products in Japan

Unit: B¥

FY17


<Global products> (Quarterly) (%) (Quarterly) (%) (Quarterly) (%) (Quarterly) (%)

XTANDI 6.5 7.0% 6.4 11.6% 7.2 15.3% 6.0 11.6%

Vesicare 6.4 -8.0% 5.7 -4.7% 6.7 -4.1% 5.0 -10.7%

Betanis 7.2 12.3% 6.9 16.8% 8.4 15.8% 7.0 9.8%

Harnal 2.1 -18.6% 1.9 -15.3% 2.0 -17.3% 1.4 -26.3%

Prograf （Including Graceptor ） 12.7 -1.5% 12.3 3.5% 13.3 0.4% 9.9 -7.8%

Funguard 2.7 -0.5% 2.8 -3.3% 3.0 -7.9% 2.0 -11.8%

<Local products in Japan>

Micardis [Family] 23.1 -6.2% 8.3 -62.4% 8.9 -66.5% 5.9 -70.0%

Micombi 2.4 -7.5% 0.9 -59.0% 1.0 -62.3% 0.6 -67.7%

Micamlo 6.7 -2.2% 2.5 -59.2% 2.7 -63.8% 1.9 -67.8%

Celecox 12.4 0.3% 12.3 4.9% 13.2 2.0% 10.4 -0.9%

Symbicort 10.2 4.1% 8.8 -0.7% 11.9 0.2% 8.5 -1.5%

Bonoteo 3.5 -4.6% 3.3 -1.7% 3.7 -3.1% 2.8 -5.2%

Geninax 2.3 -4.8% 1.7 -5.1% 3.1 -15.5% 2.1 -7.9%

Vaccines 3.4 -11.1% 3.4 -53.1% 19.5 -4.8% 3.1 4.9%

Argamate 1.5 -2.4% 1.4 0.1% 1.6 1.8% 1.2 -4.0%

Gonax 1.2 6.5% 1.2 8.2% 1.3 7.4% 1.1 -6.5%

Cimzia 2.2 14.1% 2.3 18.2% 2.5 19.0% 2.0 12.8%

Suglat 2.9 22.3% 2.9 30.4% 3.8 43.3% 2.0 -10.1%

Repatha 0.3 0.4 0.5 0.5

Linzess 0.1 0.3 0.4 0.5

Lipitor 5.4 -15.5% 5.0 -12.4% 5.4 -14.8% 3.8 -19.5%

Myslee 3.5 -11.4% 3.4 -7.2% 3.6 -8.5% 2.8 -11.0%

Seroquel 1.8 -19.9% 1.6 -15.4% 1.7 -14.2% 1.1 -21.8%

Total Rx Sales In Japanese market 106.1 -7.5% 88.0 -17.7% 114.8 -15.8% 74.4 -21.3%


3) Sales of products in Americas and EMEA Unit: B¥

FY17



Tarceva 8.3 -11.6% 8.5 0.2% 7.8 -20.4% 5.0 -33.2%

(US) 6.2 -9.1% 6.5 1.7% 5.7 -20.5% 3.1 -43.6%

(ex-US) 2.2 -18.0% 2.0 -4.5% 2.1 -20.3% 2.0 -6.3%

Scan (Americas) 18.7 -3.0% 17.9 11.0% 18.3 11.5% 18.7 -5.2%

AmBisome (Americas) 2.9 18.5% 2.8 22.0% 3.1 2.1% 2.5 -7.2%

CRESEMBA (Americas) 2.1 64.0% 2.1 72.8% 2.7 66.9% 2.7 63.1%


53

4) Sales in Americas and EMEA (Local currency)

Unit:M$

FY17


Americas (Quarterly) (%) (Quarterly) (%) (Quarterly) (%) (Quarterly) (%)

Sales 914 -8.1% 962 -0.7% 1,050 13.3% 983 7.3%

XTANDI 323 -6.8% 340 1.2% 383 24.3% 359 21.2%

US 301 -8.9% 314 -1.3% 353 20.6% 334 22.3%

Americas (ex-US) 22 36.3% 25 47.2% 30 94.1% 24 8.4%

Tarceva 75 -13.9% 77 -7.7% 69 -23.2% 47 -27.9%

US 55 -11.5% 59 -6.2% 51 -23.3% 29 -38.5%

ex-US 20 -20.2% 18 -12.3% 18 -23.0% 18 -0.5%

VESIcare 84 -33.2% 94 -31.7% 110 -7.0% 85 -22.1%

Myrbetriq 135 12.8% 160 35.3% 185 44.6% 177 22.5%

Prograf 56 -20.9% 56 -11.3% 57 -5.1% 63 8.3%

Scan 168 -5.6% 161 2.1% 162 8.2% 172 -1.0%

MYCAMINE 27 -5.6% 26 -7.0% 30 5.4% 28 1.6%

AmBisome 26 15.3% 25 12.6% 28 -1.6% 23 -2.3%

CRESEMBA 19 59.7% 19 59.5% 24 61.0% 25 69.4%

Unit:M€

FY17


EMEA (Quarterly) (%) (Quarterly) (%) (Quarterly) (%) (Quarterly) (%)

Sales 683 -2.4% 656 -7.1% 684 -7.2% 627 -2.2%

XTANDI 200 22.0% 206 13.8% 209 10.1% 208 13.5%

Eligard 35 -1.2% 30 0.2% 32 -9.7% 28 -11.7%

Vesicare 61 -13.9% 58 -16.3% 62 -10.4% 63 4.5%

BETMIGA 32 11.9% 33 13.8% 38 17.8% 37 30.6%

Omnic 34 -2.7% 38 23.1% 33 -3.7% 33 -12.2%

Sales by Astellas 31 4.9% 31 11.3% 30 -4.5% 29 -0.7%

Bulk and Royalties 2 -49.3% 7 121.9% 3 4.0% 4 -54.4%

Prograf 172 5.9% 158 3.4% 154 -0.5% 147 4.0%

Sales by Astellas 161 2.9% 152 4.3% 151 -0.3% 143 4.6%

Advagraf 71 9.2% 69 11.4% 70 8.3% 62 2.8%

Exports to third parties 11 81.2% 7 -12.7% 3 -5.2% 4 -12.2%

MYCAMINE 24 5.4% 24 -0.1% 21 -11.8% 20 1.4%


54